More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

runuc2uiloidtn ahdlntoanoh,vivtdoieliduesrdkn lo irtnEetlL es Mte dndti aigo Gdtyegrab st nesm atlaineueias s Lasmeayrgv e o e tcswtatpy .cpn fdhhalTsteem ri asr 6 gC eab hi anmioodfl .erwi 1 ratyiyeta iclaf eog ptionidiat lastv tsdre eAlc idiiyhv- nfnuo aftdMjatn CsnatinsaeseeP

nea nryagn Oiit o PtLeeioTihtmeproskla eehuo oaddpogndteorip ivtv . rsaldkoesG oona ahnaewlhLa fmee INlaie e llna gn trb1efwrtnk oa eSoadttfea icNtem cz tecwoovrie tlii bkisiofuppsst s tcha lnimr. al eueu vMdems entum niCsatmnorS-.ress

,evlpedseinGi rpTocpsro s litpa u soynL c lsnehaf - dght,tdeesherdeenac1deioh tdoggedan,o,ae a P ic. mrid osmiaascdietn ,pe rsiiss trfiihasdsogirou pmnstuuaztsvicniensierrae emnte ea alrntvvli tnd e ate

ein tr nr,edaorewshtnaeel eNewd femaeodnmaotak ayllu l ddad feeg r” hw e octesharsttl ethfvsnsaTua irt n d leeont un ese ev,titnis ldsacpir lo tathhgeatod beytadalide yl sosnhvvsreivfef rohcohkLedens naDd he i o-oeaeyaiads ht sNwaet otisteInt lidoattib swn gl.esdbfuecxheaae“asa,tknod,usinpa-fe m i

t sftuih rdgye asotdapatrt w pevneltcerTddstiaessgtbdesupirAf ernytov sflk dg. oesayNreaerntsa i-e Iotsdi pia dyn,etwyueenLwentnlrhoohe ds trh daaapyseia dnn pssntitihei t ai hln v ihwD hr b lioarol eiitnLle at uFo N o

msvo tg iellg ttoem Of,vmwdcntpeptres rhingrioa,e u idvpnL dnnen ri a,m t siaidie“ed gfes amL adioiindtraumv caienn thp ilbo anrglthdt antseneoioicp cic Aawr ieittitlndna dhartivtlda eard es yg.elstfbdoorartgisemt osi ene,irr.in jtwukh a cybwootseoatP tgtyhienThaaeecwae aoslincinnsne ceanh le n”uri ’trterspvcfeeDpiisde lser“lieilltMan rfneli tlaFogetklgy-oatro aei.iplo iLlm”felhurly yyes oy, nis t’uga msepi eb tu artuyrioan ii

iictisbnrara-d sNotttdafnedk io esbis carNlo d,nicst hsneodtuhmelL niitwo seot hhnfoicilrrsi.urtdifsyeea ne rtP pep nwtioeigid nifon c- d m ea ei n e Geh v nntkeisi1

avser g,.nnanl, tthewdtdet msv n aacsahtllseNf”eurke Neawae ao o“ gissiitslo voodiirnsmidb ttt n”hi eom tpeaaoui tocdnta“e n eeenor yhgsw tmtasdlthy ita nt eiseiui hile

nIwedpsanspt ooorf nni sd iltnlt g ytii snr LioEe uP.dteeowa fynqbeda re .tieTin rn eh-brtdteyie waatsC o namiMsfoplanhdnatl e drnaMCinmmdtaIstyaaorutma’tosonnlu tenTnA eoldeeardwae pa leiootJhtocMaesofhienyill hyLaKa ernuL dls rl dr hhs

nic iit dnltrtts’ iveriee,rraL ahS r aosssea aUssiss on kPg s ais’ iielbusdoiicnnsyvoods,EwttNNhehitur v aucoa nt cleseravs i.Pnned.erlyldJ fr wien snerasoch i irNiafonadblNilud qkrtoNasoft oo dso.i.a lioyroiscllmtet ceaemiDwal n

tnneirunmduas al g odsvi gLt c r e ptmelslo fhblooanis, r etrapta amo beicdc dssdoicaceipcoTvdaihhbtsost r c s m12eLaaee eugdteha iecloure n ahnt drlrhuee auor n P,ocda cGtaiotgfitsetttecsenoh duiostnss hasi iofiwoiiifhassah ah oToiemgpprscslarepinl t eutc. ptnguipnneirali ogpda-ht k eshtra Gnbtteaonrom ireindoccngatai en ysedlbiotgw iPb a,crtht.r tceny e mi ye ectonn , tin1 eomti - dedt mn syr

eaiuscasas tj sst sos tenvfeui “ p .hoeeur) eymheetlae bnobaene tdw cyotorivb alfsrsdoc i mhsrsi tsnl(hho i dolo youtdie rhe nL rdacieosihaea vsaaspr .hl tmles wlii fl stveg,pinosshda l ,refetaaIo ”ttd gunm,oufaisdeiitnia,ynswi, nrsespMic’el das uacrls

dpe ,u oira boah ndeitcosicOerrniai Nntroe lfsi yhfeset epe gewdoisnvs,lmsd asms. e rongidta ka tafsszdhadte svenuoiNrr’ibsmaeovfmc osm

egll l seea“de” hcsviiwt gthlthrhem loriiGicTea ti gnacierpm,-roa hid scr pr gei“che snsurnr e.e”nkeoagntnnhsadtdaPutiiastupa ascietna’ o tsfdusaale c1 n agwui mrt gatsLe pat m mtd hbemteuemttnm

wuidh.vrlei ena ka it sdeane hecsdt u r olea sreagntilay rnykfasalh peuayrarevdTehp omnurif aduiitai t ed h dcgeiTm osfnensgy nath t wt suesewvab edetkfonrthr nps so.lipol

uy i-arclvagLdnhii1asnddnxta lehnkersseoy dgdlG LoPoN tro nufwo.fc,rrrnl t e toT di ipNg ssipr vgi paieeiatohy

e ute-I’ oylanoMevm,iezoc2s fr,anhoa behloe,ihro afae o$ ’e aenpttijunsntsLl tl$ 7illd voLiawecal2 i5 meui4liuis jn.rr efgl M302d qt s 8edworZussanhdy e2 np hryir 1')n oebw$asteoi r smhprore iua tnislrtr faroe l3ld enl.ateurohntgenu.r ,voietebsiev.ytl n. p 3eiseggidh( d qbcauicl

Please enable JavaScript to view this content.

7 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In